Medivation to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference

Medivation, Inc. (AMEX:MDV) today announced that it will
present at the Rodman & Renshaw 3rd Annual Global Healthcare
Conference to be held at the Le Meridien Beach Plaza Hotel in Monte
Carlo, Monaco on May 15-16, 2006.
   David Hung, MD, President and Chief Executive Officer of
Medivation, will present on Monday, May 15, 2006 at 11:55 a.m. local
time (5:55 a.m. Eastern time) and will discuss the Company's strategic
initiatives, product pipeline and market opportunities.
   Interested parties can access a live audio webcast and
accompanying slide presentation via the Internet by visiting the
Investors section on the Company's Web site at www.medivation.com. The
presentation will be archived on the Web site and available for 30
days.

   About Medivation

   Medivation, Inc. acquires promising pharmaceutical and medical
device technologies in the late preclinical development phase, and
develops those technologies quickly and cost-effectively through human
first proof-of-efficacy studies (generally the end of Phase 2 clinical
trials). Depending on the indication, Medivation will either seek to
sell or partner successful programs with larger pharmaceutical,
biotechnology and medical device companies for late-stage clinical
studies and commercialization, or alternatively conduct those
activities internally. The Company intends to build and maintain a
portfolio of 4 to 6 development programs at all times.
   Medivation's current portfolio consists of small molecule drugs in
development to treat 3 large, unmet medical needs -- Alzheimer's
disease, Huntington's disease and hormone-refractory prostate cancer,
the last two of which are likely Orphan Drug indications. Dimebon(TM),
with a 20-year record of human use and demonstrated efficacy in animal
studies of both Alzheimer's disease (AD) and Huntington's disease (HD)
and in a pilot clinical study of AD, is in a randomized, double-blind,
placebo-controlled Phase 2 study in AD patients in Russia, the results
of which are expected to be available in Q3 2006. Medivation also
expects to initiate a Phase 1-2a study of Dimebon in HD patients in
2006. The MDV300 series compounds are in development for the treatment
of hormone-refractory prostate cancer, and are expected to enter
clinical studies in the first half of 2007. Further information about
Medivation can be found on its website (www.medivation.com).

   Safe Harbor Statement

   This press release contains forward-looking statements, including
statements regarding the anticipated timing of regulatory and clinical
milestones on the Company's Alzheimer's disease, Huntington's disease
and hormone-refractory prostate cancer programs, which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements involve
risks and uncertainties that could cause actual results to differ
significantly from those projected. You are cautioned not to place
undue reliance on the forward-looking statements, which speak only as
of the date of this release. Our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-KSB for
the year ended December 31, 2005, include more information about
factors that could affect our financial and operating results.